• Je něco špatně v tomto záznamu ?

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine Booster Doses in Kidney Transplant Recipients: Results of a 12-mo Follow-up From a Prospective Observational Study

V. Petr, I. Zahradka, I. Modos, M. Roder, M. Fialova, J. Machkova, K. Kabrtova, P. Hruba, M. Magicova, A. Slavcev, I. Striz, O. Viklicky

. 2024 ; 10 (6) : e1645. [pub] 20240517

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24012646

BACKGROUND: Booster doses of SARS-CoV-2 mRNA vaccines are commonly used in kidney transplant recipients (KTRs). However, there is uncertainty regarding the waning of vaccination responses and immunological safety in KTRs. METHODS: A total of 123 KTRs were included in the final analysis of this prospective observational cohort study. The aim was to evaluate the immunogenicity and immunological safety. SARS-CoV-2 antispike IgG antibodies and anti-HLA antibodies were measured at baseline and then at months 3, 6, and 12 after vaccination with the first booster dose (ie, the third vaccine dose). Antibodies against S1 and S2 subunits of SARS-CoV-2 were evaluated using an immunochemiluminescent assay (cutoff 9.5 AU/mL, sensitivity 91.2%, and specificity 90.2%). Anti-HLA antibodies were analyzed using single-antigen bead technology. RESULTS: Seroconversion was reached in 65% of KTRs previously nonresponding to 2-dose mRNA vaccination; the overall seroconversion rate 3 mo after the first booster dose was 83%. Vaccination induced a durable humoral response, and the antibody levels were stable during the 12-mo study follow-up. Higher age (exponentiated beta coefficient [eβ] 0.97; 95% confidence interval [CI], 0.943-0.997) and a full dose of mycophenolate (eβ 0.296; 95% CI, 0.089-0.984) were negatively associated with SARS-CoV-2 IgG antibody levels, whereas better graft function (eβ1.021; 95% CI, 1.005-1.037) was associated positively. There were no systematic signs of anti-HLA antibody development after vaccination. However, during the follow-up, there was a nonsignificant signal of an increase in anti-HLA antibodies in those who developed COVID-19. CONCLUSIONS: Additional booster doses of SARS-CoV-2 mRNA vaccines induce durable antibody response even in a large subset of previous nonresponders and are not associated with the risk of allosensitization. Furthermore, a signal linking COVID-19 to the development of anti-HLA antibodies was observed, and this should be confirmed and further examined (NCT05483725).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012646
003      
CZ-PrNML
005      
20240726151410.0
007      
ta
008      
240723s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/TXD.0000000000001645 $2 doi
035    __
$a (PubMed)38769974
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Petr, Vojtech $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
245    10
$a Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine Booster Doses in Kidney Transplant Recipients: Results of a 12-mo Follow-up From a Prospective Observational Study / $c V. Petr, I. Zahradka, I. Modos, M. Roder, M. Fialova, J. Machkova, K. Kabrtova, P. Hruba, M. Magicova, A. Slavcev, I. Striz, O. Viklicky
520    9_
$a BACKGROUND: Booster doses of SARS-CoV-2 mRNA vaccines are commonly used in kidney transplant recipients (KTRs). However, there is uncertainty regarding the waning of vaccination responses and immunological safety in KTRs. METHODS: A total of 123 KTRs were included in the final analysis of this prospective observational cohort study. The aim was to evaluate the immunogenicity and immunological safety. SARS-CoV-2 antispike IgG antibodies and anti-HLA antibodies were measured at baseline and then at months 3, 6, and 12 after vaccination with the first booster dose (ie, the third vaccine dose). Antibodies against S1 and S2 subunits of SARS-CoV-2 were evaluated using an immunochemiluminescent assay (cutoff 9.5 AU/mL, sensitivity 91.2%, and specificity 90.2%). Anti-HLA antibodies were analyzed using single-antigen bead technology. RESULTS: Seroconversion was reached in 65% of KTRs previously nonresponding to 2-dose mRNA vaccination; the overall seroconversion rate 3 mo after the first booster dose was 83%. Vaccination induced a durable humoral response, and the antibody levels were stable during the 12-mo study follow-up. Higher age (exponentiated beta coefficient [eβ] 0.97; 95% confidence interval [CI], 0.943-0.997) and a full dose of mycophenolate (eβ 0.296; 95% CI, 0.089-0.984) were negatively associated with SARS-CoV-2 IgG antibody levels, whereas better graft function (eβ1.021; 95% CI, 1.005-1.037) was associated positively. There were no systematic signs of anti-HLA antibody development after vaccination. However, during the follow-up, there was a nonsignificant signal of an increase in anti-HLA antibodies in those who developed COVID-19. CONCLUSIONS: Additional booster doses of SARS-CoV-2 mRNA vaccines induce durable antibody response even in a large subset of previous nonresponders and are not associated with the risk of allosensitization. Furthermore, a signal linking COVID-19 to the development of anti-HLA antibodies was observed, and this should be confirmed and further examined (NCT05483725).
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zahradka, Ivan $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Modos, Istvan $u Information Technology Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Roder, Matej $u Immunogenetics Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Fialova, Martina $u Department of Clinical and Transplant Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Machkova, Jana $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kabrtova, Katerina $u Immunogenetics Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Hruba, Petra $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Magicova, Maria $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Slavcev, Antonij $u Immunogenetics Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Striz, Ilja $u Department of Clinical and Transplant Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Viklicky, Ondrej $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $1 https://orcid.org/0000000310492195 $7 nlk20050170291
773    0_
$w MED00195744 $t Transplantation direct $x 2373-8731 $g Roč. 10, č. 6 (2024), s. e1645
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38769974 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151403 $b ABA008
999    __
$a ok $b bmc $g 2125429 $s 1224509
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 10 $c 6 $d e1645 $e 20240517 $i 2373-8731 $m Transplantation direct $n Transplant Direct $x MED00195744
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Možnosti archivace